RGD Reference Report - Sensitization of radio-resistant prostate cancer cells with a unique cytolethal distending toxin. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Sensitization of radio-resistant prostate cancer cells with a unique cytolethal distending toxin.

Authors: Lai, Chih-Ho  Chang, Chia-Shuo  Liu, Hsin-Ho  Tsai, Yuh-Shyan  Hsu, Feng-Ming  Yu, Yung-Luen  Lai, Cheng-Kuo  Gandee, Leah  Pong, Rey-Chen  Hsu, Heng-Wei  Yu, Lan  Saha, Debabrata  Hsieh, Jer-Tsong 
Citation: Lai CH, etal., Oncotarget. 2014 Jul 30;5(14):5523-34. doi: 10.18632/oncotarget.2133.
RGD ID: 401901597
Pubmed: PMID:25015118   (View Abstract at PubMed)
PMCID: PMC4170639   (View Article at PubMed Central)
DOI: DOI:10.18632/oncotarget.2133   (Journal Full-text)

Cytolethal distending toxin (CDT) produced by Campylobacter jejuni is a genotoxin that induces cell-cycle arrest and apoptosis in mammalian cells. Recent studies have demonstrated that prostate cancer (PCa) cells can acquire radio-resistance when DOC-2/DAB2 interactive protein (DAB2IP) is downregulated. In this study, we showed that CDT could induce cell death in DAB2IP-deficient PCa cells. A combination of CDT and radiotherapy significantly elicited cell death in DAB2IP-deficient PCa cells by inhibiting the repair of ionizing radiation (IR)-induced DNA double-strand break (DSB) during G2/M arrest, which is triggered by ataxia telangiectasia mutated (ATM)-dependent DNA damage checkpoint responses. We also found that CDT administration significantly increased the efficacy of radiotherapy in a xenograft mouse model. These results indicate that CDT can be a potent therapeutic agent for radio-resistant PCa.




  
Object Symbol
Species
Term
Qualifier
Evidence
With
Notes
Source
Original Reference(s)
DAB2IPHumanprostate cancer treatmentIMP human cells in mouse modelRGD 
Dab2ipRatprostate cancer treatmentISODAB2IP (Homo sapiens)human cells in mouse modelRGD 
Dab2ipMouseprostate cancer treatmentISODAB2IP (Homo sapiens)human cells in mouse modelRGD 


Genes (Rattus norvegicus)
Dab2ip  (DAB2 interacting protein)

Genes (Mus musculus)
Dab2ip  (disabled 2 interacting protein)

Genes (Homo sapiens)
DAB2IP  (DAB2 interacting protein)